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Abstract
Background: Estradiol valerate (EV)-induced polycystic ovaries (PCO) in rats is associated with
an increase in ovarian sympathetic outflow. Low-frequency (2 Hz) electro-acupuncture (EA) has
been shown to modulate sympathetic markers as well as ovarian blood flow as a reflex response
via the ovarian sympathetic nerves, in rats with EV-induced PCO.
Methods: In the present study, we further tested the hypothesis that repeated 2 Hz EA treatments
modulate ovarian sympathetic outflow in rats with PCO, induced by a single i.m. injection of EV, by
investigating the mRNA expression, the amount and distribution of proteins of α 1a-, α 1b-, α 1d-,
and β 2-adrenoceptors (ARs), as well as the low-affinity neurotrophin receptor (p75NTR).
Results: It was found that EV injection results in significantly higher mRNA expression of ovarian
α 1b- and α 1d-AR in PCO rats compared to control rats. The p75NTR and β 2-ARs mRNA
expression were unchanged in the PCO ovary. Low-frequency EA resulted in a significantly lower
expression of β 2-ARs mRNA expression in PCO rats. The p75NTR mRNA was unaffected in both
PCO and control rats. PCO ovaries displayed significantly higher amount of protein of α 1a-, α 1b-
and α 1d-ARs, and of p75NTR, compared to control rats, that were all counteracted by repeated
low-frequency EA treatments, except for α 1b-AR.
Conclusion: The present study shows that EA normalizes most of the EV-induced changes in
ovarian ARs. Furthermore, EA was able to prevent the EV-induced up regulation of p75NTR,
probably by normalizing the sympathetic ovarian response to NGF action. Our data indicate a
possible role of EA in the regulation of ovarian responsiveness to sympathetic inputs and depict a
possible complementary therapeutic approach to overcoming sympathetic-related anovulation in
women with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous
endocrine and metabolic disorder recognized as the pri-
mary cause of infertility in women of the reproductive age
[1]. The syndrome is associated with ovulatory dysfunc-
tion, abdominal obesity, hyperandrogenism, and pro-
found insulin resistance [1].
The precise etiology of the disease is unknown, even
though the disturbances detected in PCOS has been attrib-
uted to primary defects in the hypothalamus-pituitary-
adrenal (HPA) axis, the ovarian microenvironment, the
adrenal gland, and the insulin/insulin-like growth factor
(IGF)-I metabolic regulatory system [1]. That the sympa-
thetic nervous system may be a primary factor in the
development and maintenance of PCOS has been sug-
gested by several investigators [2-5].
The utility of murine models of polycystic ovaries (PCO)
has been discussed [6]. Even though it is impossible to
reproduce human PCOS in an animal model, such a
model may provide important leads. Studies on adult nor-
mal cycling rats found that a single intramuscular (i.m.)
injection of estradiol valerate (EV) causes acyclicity and
formation of PCO [7]. The EV-induced rat PCO model
reflects some endocrinological and morphological charac-
teristics of human PCOS, and it is assumed that activity in
the ovarian sympathetic nerves is higher than in normal
rats [8-10]. This is evidenced by an early increase in ovar-
ian levels of norepinephrine (NE), an enhanced release of
NE from ovarian nerve terminals, an increased activity of
the catecholamine synthesis-limiting enzyme tyrosine
hydroxylase (TH), and down-regulation of β 2-adrenocep-
tors (ARs) in theca-interstitial cells [8-10].
The expression of other types of ARs in the ovary, namely
the α 1-ARs, has been evaluated by functional studies. α 1-
ARs are members of the G protein-coupled receptors and
play critical roles in the regulation of a variety of physio-
logical processes [11]. Within this classification, there are
three subtypes: α 1a, α 1b, and α 1d [11]. The α 1a-AR subtype
has been reported to be implicated in the maintenance of
vascular basal tone, the α 1b-AR subtypes to participate in
the response to exogenous agonists, and that the α 1d-AR
subtype is a predominant mediator of arterial vasocon-
striction. In vitro studies have demonstrated that α -AR are
involved in the regulation of ovarian blood flow [12] and
most probably in the ovarian steroidogenesis [13]. In a
recent study, we found that the expression of all the α 1-AR
subtypes in the ovaries of PCO rats significantly differs
from that of controls and varies at different time points
after EV injection, indicating a possible participation of
this ARs in the development of EV-induced PCO [14].
It has been demonstrated that the development of ovarian
follicular cysts in steroid-induced PCO in rats is preceded
by an increased synthesis of ovarian nerve growth factor
(NGF) and low-affinity neurotrophin receptor (p75NTR)
mRNA [10]. Thus, blocking the actions of intra-ovarian
NGF restores estrus cyclicity as well as structural and func-
tional features of the ovary in EV-induced PCO in rats
[10], suggesting that hyper activation of sympathetic
input in PCO is related to an overproduction of NGF.
Electro-acupuncture (EA) is a non-pharmacological
method known to initiate a number of reactions at the
spinal level and centrally in the brain [15,16]. We have
recently demonstrated that repeated low-frequency EA
treatments induced regular ovulations in more than one-
third of the women affected by PCOS and normalized
endocrine and neuroendocrine parameters without any
negative side-effects [17]. These observation suggest that
EA effects are mediated through inhibition of the activity
of the sympathetic nervous system since EA is known to
modulate various autonomic functions [17]. Moreover,
using the steroid-induced PCO model, we found that
repeated treatments of low-frequency EA in somatic seg-
ment related to the innervation of the ovary, reduced high
concentrations of ovarian NGF, corticotrophin-releasing
factor (CRF), and endothelin-1 as well as increased low
concentrations of hypothalamic β -endorphin [18-21].
Furthermore, low-frequency EA increases ovarian blood
flow as a reflex response via the ovarian sympathetic
nerves, whereas high frequency decreases ovarian blood
flow as a passive response following systemic circulatory
changes in both normal and PCO rats [22,23]. These
results suggest that repeated treatments of low-frequency,
but not high frequency EA, can inhibit high activity in the
autonomic nervous system. However, the mechanism
implicated in this event is not clearly known.
The present study was undertaken to investigate the effect
of repeated treatments of low-frequency EA on ovarian
sympathetic innervation in rats with steroid-induced
PCO. To address this question, we studied the mRNA
expression and protein amount and distribution of the
sympathetic markers α 1a-, α 1b-, α 1d-, and β 2-AR, and of
p75NTR.
Materials and methods
Animals
Thirty-two virgin adult cycling Wistar Kyoto rats (Mölle-
gaard, Denmark) weighing 205-230g were housed four to
a cage at a controlled temperature of 22°C with a 12-h
light:12-h dark cycle for at least 1 week before and
throughout the experimental periods. The rats had free
access to pelleted food and tap water. Sixteen rats, those in
the two PCO groups described below, were each given a
single i.m. injection of 4 mg EV (Riedeldehaen, Germany)Reproductive Biology and Endocrinology 2005, 3:21 http://www.rbej.com/content/3/1/21
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in 0.2 ml oil, to induce well-defined PCO [7,18]. Sixteen
rats, those in the two Oil groups described below, received
a single i.m. injection of 0.2 ml oil (arachidis oleum,
Apoteket AB, Umeå, Sweden) only. Thirty to thirty-three
days after i.m. injection of EV, i.e. 2 days after the last EA
treatment, the rats was killed by decapitation. The injec-
tions and the finalizing of the experiment was done inde-
pendent of cycle day [7,18]. The experiments were carried
out according to the principles and procedures outlined in
the National Institute of Health (NIH) Guide for the Care
and Use of Laboratory Animals and were approved by the
local animal ethics committee at Göteborg University,
Göteborg, Sweden
Electro-acupuncture treatment
The rats were divided into four experimental groups: i) an
Oil group (control, n = 8), ii) an Oil group receiving EA
(EA, n = 8), iii) a PCO group (PCO, n = 8), and iv) a PCO
group receiving EA (PCO+EA, n = 8).
All groups were anaesthetized for 25 minutes on 12 occa-
sions as described below. The EA and the PCO+EA groups
received EA every second day during anesthesia. The EA
and the PCO+EA group underwent the first EA treatment
2 days after the EV injection. The points chosen for stimu-
lation were bilateral in the mm. biceps femoris and erec-
tor spinae, in somatic segments corresponding to the
innervation of the ovaries (Figure 1). The needles (Hegu:
Hegu AB, Landsbro, Sweden) were inserted to depths of
0.5-0.8 cm and then attached bilaterally to an electrical
stimulator (CEFAR ACUS 4, Cefar, Lund, Sweden). The
points were electrically stimulated with a low burst fre-
quency of 2 Hz; each pulse had a duration of 180 µsec, a
burst length of 0.1 sec, and a burst frequency of 80 Hz.
The intensity (1.5-2 mA) was adjusted until local muscle
contractions were observed to reflect the activation of
muscle-nerve afferents (A-delta fibers and possibly C fib-
ers). The location and type of stimulation were the same
in all rats.
Anaesthetization
During each treatment, all rats were anaesthetized super-
ficially with an intraperitoneal (i.p.) injection of a mixture
of Ketamin (50 mg/kg; PARKE-DAVIS, Warner Lambert
Nordic AB, Solna, Sweden) and Rompun (20 mg/kg;
Bayer, Bayer AG, Leverkusen, Germany). On day 30 after
the i.m. injection of EV, the rats was decapitated, that is,
1-2 days after the last EA treatment.
Tissues
At the completion of the experiment, the ovaries were
quickly dissected on dry ice. One ovary was divided in two
pieces, weighed, and snap frozen in liquid nitrogen and
stored at -80°C until extraction. The second ovary was
fixed in buffered 4% formaldehyde for at least 24 hours in
preparation for AR, and p75NTR immunohistochemistry.
Real-Time PCR for adrenoceptors
Total RNA from the ovary was extracted using RNeasy
Mini kits (Qiagen, Hilden, Germany). First-strand cDNA
was synthesized from 1 µg of total RNA with TaqMan
reverse transcription reagents (Applied Biosystems., Foster
City, CA). Each 100 µl RT-PCR reaction contained 1 µg of
total, 1X TaqMan RT buffer, 5 mM MgCl2, 2.5 mM ran-
dom hexamers, 1 mM dNTP, 0.4 U/ml RNase inhibitor,
and 1.25 U/ ml Multiscribe RT (PE Applied Biosystems,
Foster City, CA, USA). Reverse transcription was carried
out in a PTC-200 PCR system (MJ Research., Boston, MA,
Schematic drawing of the placement and stimulation of the  acupuncture needles Figure 1
Schematic drawing of the placement and stimulation of 
the acupuncture needles. Two needles were placed bilater-
ally in m. erector spinae at the level of Th12 and two were 
placed in m. quadriceps bilaterally. The needles were then 
attached to an electrical stimulator for electro-acupuncture 
(EA) treatment. Reprinted with permission from Biol Reprod 
(2000) 63:1507-1513.
EA
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USA) at 25°C for 10 min, 48°C for 30 min and 95°C for
5 min.
The polymerase chain reaction (PCR) analysis was per-
formed using the ABI Prism 7700 Sequence Detection Sys-
tem (PE Applied Biosystems, Stockholm, Sweden) and
FAM-labeled probe specific for α 1a-AR (Rn00567876m1),
α 1b-AR (ADRA A1B-EX 152027A02), α 1d-AR
(Rn00577931ml), and β 2-AR (Rn00560650s1) (PE
Applied Biosystems). Designed primers and a VIC-labeled
probe for Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (NM_031144) were included in the reactions
as an internal standard. cDNA was amplified under the
following conditions: 1 cycle at 50°C for 2 min and 95°C
for 10 min, followed by 40 cycles at 95°C for 15 s and
60°C for 1 min. The amount of mRNA of each gene was
calculated using the standard curve method (following
the instructions in User Bulletin no. 2, PE Applied Biosys-
tems) and adjusted for the expression of GAPDH.
Reverse Transcriptase-PCR-ELISA for p75NTR
The expression of p75NTR-mRNA was evaluated using the
reverse transcriptase (RT)-PCR enzyme-linked immuno-
sorbent assay (ELISA) protocol, exactly as previously
described by Tirassa and co-workers [24]. Total RNA was
extracted from the ovaries using the method of Chomc-
zynski and Sacchi [25] as modified in the TRIzol Kit (Inv-
itrogen AB, Lidingö, Sweden). Complementary DNA was
synthesized from 1 µg of total RNA using 250 ng Oligo
(dT)12–18 primer and 200 Units of M-MLV RT (Promega
Italia, Milan, Italy) in 20 µl of total volume reaction. p75
and GAPDH genes were co-amplified in a single-tube PCR
reaction (35 cycles: 1 min at 95°C; 1 min at 55°C; 2 min
at 72°C) using 5'-biotinylated specific primers to generate
biotinylated PCR products detectable by digoxygenin-
labeled probes in an immuno-enzymatic assay. Primer/
probe sequences are as follows: p75NTR biotinylated for-
ward:  5'CGTGTT CTCCTGCCAGGACA3'; p75NTR reverse:
5'GAGATGCCACTGTCGCTGTG3'; p75NTR  digoxygenin-
labeled probe:
5'ACAGCAGCCAAGATGGAGCAATAGACAGG3'; GAPDH
biotinylated forward: 5'CACCACCATGGAGAAGGCC3';
GAPDH reverse: 5'GATGGATGCCTTGGCCAGG3';
GAPDH digoxygenin-labeled probe:
5'ACAATCTTGAGTGAGTTGTCATATTTCTCG3'. The
amount of amplified products was measured at an optical
density (O.D.) of 450/690 nm (O.D. 450/690) using a
Dynatech ELISA Reader 5000. A GAPDH level of O.D.
450/690 was used to normalise the relative differences in
sample size, differences in the integrity of the individual
RNA, and variations in RT efficiency. For exact methodo-
logical details see Tirassa et al. [24].
Immunohistochemistry for adrenoceptors and p75NTR
Commercially available antibodies were used to detect
α 1a-AR (α 1a-AR [C-19]: sc-1477, Santa Cruz, California,
USA), α 1b-AR (α 1b-AR [C-18]: sc-1476, Santa Cruz, Cali-
fornia, USA), α 1d-AR (α 1d-AR [H-142]: sc-10721, Santa
Cruz, California, USA), and β 2-AR (β 2-AR [M-20]: sc-1570,
Santa Cruz, California, USA) by immunohistochemistry.
The monoclonal antibody anti-p75NTR (clone 192) [26]
was produced and purified in our laboratory.
Serial, 15-µm thick sections of each ovary were cut with a
cryostat and processed for immunohistochemistry.
Briefly, sections were blocked with a 10 minutes incuba-
tion in 3% hydrogen peroxide and 10% methanol in PBS
containing 0.1% Triton X-100 (PBST), followed by a 30
minutes incubation in 10% normal serum dissolved in
PBST. Then, sections were incubated overnight at 4°C
with the primary antibody diluted in PBST (rabbit and
goat anti-ARs: 5 µg/ml; monoclonal anti p75NTR: 1 µg/
ml). Sections were then incubated with biotinylated anti-
rabbit IgG (α 1d- and β 2-AR), anti-goat IgG (α 1a- and α 1b-
AR) or anti-mouse IgG (p75NTR) antibodies (all of them
from Vector Lab. Inc., Burlingame, CA, and used accord-
ing to manufacturer instructions at 1:300 dilution)
diluted in PBST. Diaminobenzidine was used to detect the
immuno-complex. To assess staining specificity, sections
were incubated with non-specific rabbit, goat or mouse
IgG (Zymed Lab Inc, San Francisco, Ca) and used as con-
trols. Immunostained sections were evaluated under the
Nikon Eclypse E600 microscope equipped with the Nikon
DMX 1200 digital camera connected to a PC computer.
Sections were coded, and positive cells were counted in 10
sections coming from 5 different ovaries (i.e. 2 sections
per ovary) per experimental group. Cell count was carried
out using the image processing and analysis program
Nikon-Lucia, and measurements were standardized
between the experimental groups using the same calibra-
tion system and threshold (see below). The number of
immunoreactive cells (mean ± SEM) was determined in
20× magnification images over an image area of 40000
µm2. Five non-overlapping areas per section were
counted. Since the image analyzer determines the optical
density of immunoreactions using a grey scale threshold-
ing operation, measurements were standardized between
groups using the following criteria: 1) all measurements
were conducted after the same calibration of the image
analysis system, 2) thresholding was carried out to the
same value for each image, 3) the grey scale was calibrated
to a range of 25-150 arbitrary units. Objects with higher or
lower grey levels were not considered. A morphological
program, which selects only cell bodies – but not small
fragments or cells that do not have a complete soma – was
also used to quantify immunopositive cells.Reproductive Biology and Endocrinology 2005, 3:21 http://www.rbej.com/content/3/1/21
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Statistical analyses
All statistical evaluations were performed using the Stat
View package for Macintosh (Abacus Concepts Inc., Ber-
keley, CA, USA). mRNA expression and immunopositive
cell counts of α 1- and β 2-ARs, and p75NTR in the ovaries
were evaluated using one-way analysis of variance
(ANOVA), and the groups were tested using multiple
comparisons with the correction of Fisher PSD. All results
are reported as a mean ± standard error of the mean
(SEM). A p-value less than 0.05 was considered
significant.
Results
Ovarian expression and distribution of α 1a-AR
The mRNA expression of α 1a-AR in the ovary was unal-
tered in the PCO group compared to the control group.
Repeated low-frequency EA treatments did not affect the
mRNA expression of α 1a-AR in the EA or the PCO+EA
groups (Figure 2A).
Significantly higher number of immunopositive cells of
α 1a-AR was found in the PCO group compared with the
control group. EA treatments prevented the increase in α 1a-
AR protein immunoreactivity, since the number of immu-
nostained cells in the PCO+EA group was not different
from the control group. EA treatments did not affect the
number of immunopositive cells in the ovaries of control
rats. Immunohistochemical analysis on serial sections
showed that α 1a-AR protein (Figure 2C and 2D) was
expressed mainly around blood vessels and granulosa
regions.
Ovarian expression and distribution of α 1b-AR
The mRNA expression of α 1b-AR in the ovary was signifi-
cantly higher in the PCO group than in the control and EA
group. The mRNA expression of α 1b-AR was significantly
higher in the PCO+EA group compared to the two control
groups but not to the PCO group (Figure 3A).
As illustrated in Figure 3B, significantly higher number of
immunopositive cells of α 1b-AR was found in the ovaries
of PCO and PCO+EA rats when compared to controls. EA
treatments did not affect the amount or distribution of
α 1b-AR protein in the EA and the PCO groups. As shown in
Figure 3C–D, α 1b-AR protein was located around blood
vessels and in the granulose region of mature follicles.
Ovarian expression and distribution of α 1d-AR
The mRNA expression of α 1d-AR in the ovary was signifi-
cantly higher in the PCO group than in the control group.
The mRNA expression of α 1d-AR in the PCO+EA was not
different from that in the PCO group (Figure 4A).
As illustrated in Figure 4B, significantly higher number of
immunopositive cells of α 1d-AR was found in the PCO
group compared with the control group. EA treatment signif-
icantly decreased the number of immunopositive cells in
the  PCO+EA group. The α 1d-AR immunopositive cell
number was not affected in the EA group when compared
to control group. As shown in Figure 4C–D, the α 1d-AR was
found expressed in the granulosa cells of healthy follicles
and corpora lutea, and around blood vessels (not shown)
in all of the experimental groups.
Ovarian expression and distribution of β 2-AR
The mRNA expression of β 2-AR in the ovary of the PCO
group  was not changed, when compared to the control
group. β 2-AR mRNA was significantly lower both in the EA
group and in the PCO+EA group when compared to the con-
trol group (Figure 5A).
No difference in number of β 2-AR immunoreactive cells
was found in PCO ovaries (Figure 5B), while EA treat-
ments in PCO rats (PCO+EA group) significantly increase
the amount of β 2-AR immunostained cells when com-
pared to PCO group. β 2-AR immunopositive cell number
in control ovaries was unchanged by EA treatments. The
β 2-AR was found expressed in degenerating corpora lutea
(Figure 5C) and follicles (Figure 5D) in all of the experi-
mental groups.
Ovarian expression and distribution of p75NTR
The p75NTR mRNA expression in the ovary (Figure 6A) was
unchanged in the PCO group compared to the control
group. Low-frequency EA treatments did not affect ovarian
p75NTR mRNA expression in the PCO+EA group compared
to the PCO group, and did not differ from the control group.
As shown in Figure 6B, the number of p75NTR -stained
cells in the PCO group was significantly higher than in con-
trols, while repeated EA treatments significantly decreased
p75NTR protein immunoreactivity in the PCO+EA group.
The number of ovarian p75NTR immunopositive cells was
significantly lower in the EA group when compared to con-
trols. As shown in Figure 6C–D, ovarian p75NTR expressing
cells were distributed mainly around the follicles in the
theca layers, with some immunoreactivity also spread in
the ovarian stroma (Figure 6D).
Discussion
The aim of the present study was to investigate whether
repeated low-frequency EA treatments modulate the
expression of mRNA and the amount and distribution of
proteins of α 1-, and β 2-ARs, and p75NTR in rats with ster-
oid-induced PCO. The results of this study demonstrated
that i.m. EV injections result in significantly higher mRNA
expression of ovarian α 1b- and α 1d-AR in PCO rats com-
pared to control rats. EV-induced PCO induced a signifi-
cantly higher amount of immunostained cells for α 1a-,
α 1b- and α 1d proteins, that was prevented by repeated low-Reproductive Biology and Endocrinology 2005, 3:21 http://www.rbej.com/content/3/1/21
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Ovarian α 1a-AR mRNA and protein expression Figure 2
Ovarian α 1a-AR mRNA and protein expression. As shown in panel A, no significant differences were found in α 1a-AR mRNA 
expression between the control, EA, and PCO groups. Values are given as means ± SEMs normalized to GAPDH. The results 
of α 1a-AR immunopositive cell count is shown in panel B. Values are given as means ± SEMs. Immunostaining revealed that 
ovarian α 1a-AR protein is expressed in control group ovaries. EA treatments did not affect the number of immunopositive cells 
in the ovaries of control rats. PCO ovaries had significantly higher amounts of α 1a-AR protein compared with control ovaries. 
EA treatments in PCO rats decreased α 1a-AR protein immunoreactivity when compared with untreated PCO rats. ap < 0.05 vs 
control group. bp < 0.05 vs PCO group. Representative pictures showing the distribution of α 1a-AR positive cells in the ovaries 
of the experimental groups are showed in Panel: C-D. Immunostained cells (arrows) were localized around blood vessels (C) 
and in the granulosa cells of an early antral follicle (D) and corpora lutea. F: Follicle; bv: blood vessel; gr: granulose cells; th: the-
cal layer. Magnification C: ×400; D: ×200.
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Ovarian α 1b-AR mRNA and protein expression Figure 3
Ovarian α 1b-AR mRNA and protein expression. As shown in panel A, no significant differences were found in α 1b-AR 
mRNA between the control and EA groups. A significant increase in ovarian α 1b-AR mRNA was found in the PCO group when 
compared to controls. No differences were found between the PCO+EA group and the PCO group. Values are given as means ± 
SEMs normalized to GAPDH. ap < 0.05 vs control group. EA treatments did not affect the amount of α 1b-AR immunopositive 
cells in the EA group(panel B). Significantly higher number of immunopositive cells of α 1b-AR was found in the ovaries of PCO 
rats. EA treatments did not affect the amount or distribution of α 1b-AR protein in PCO ovaries. Values are given as means ± 
SEM. ap < 0.05 vs control group. Representative pictures showing the distribution of α 1b-AR positive cells in the ovaries of the 
experimental groups are showed in Panels C-D. Immunostained cells (arrows) were localized around blood vessels (C) and in 
the granulosa cells of mature follicles (D). F: Follicle; bv: blood vessel; gr: granulose cells; th: thecal layer. Magnification C: ×400; 
D: ×200.
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Ovarian α 1d-AR mRNA and protein expression Figure 4
Ovarian α 1d-AR mRNA and protein expression. As shown in panel A, α 1d-AR mRNA expression was significantly higher in 
the PCO group than in control and EA group. EA significantly decreased the mRNA expression in the PCO+EA group compared 
with the PCO group. Values are given as means ± SEMs normalized to GAPDH. ap < 0.05 vs control group. The α 1d-AR immu-
nopositive cell number (Panel B) was not affect in the EA group when compared to control group. Significantly higher number of 
immunopositive cells of α 1d-AR was found in the PCO group compared with the control group. EA treatment significantly 
decreased the number of immunopositive cells in the PCO+EA group. Values are given as means ± SEMs. ap < 0.05 vs control 
group. bp < 0.05 vs PCO group. Representative pictures showing ovarian distribution of α 1d-AR expressing cells (pointed by 
arrows) are showed in Panels C-D. The α 1d-AR was found expressed in the granulosa cells of healthy follicles (C) and corpora 
lutea (D) and around blood vessels (not shown) in all of the experimental groups. F: Follicle; gr: granulose cells; th: thecal layer. 
Magnification C-D: ×200.
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Ovarian β 2-AR mRNA and protein expression Figure 5
Ovarian β 2-AR mRNA and protein expression. The expression of β 2-AR mRNA in the ovary (panel A) in the PCO group was 
lower compared to the control group. β 2-AR mRNA was unaltered in the PCO+EA group when compared to control. Values are 
given as means ± SEMs normalized to GAPDH. ap < 0.05 vs control group. β 2-AR immunopositive cell number (Panel B) in con-
trol ovaries was unchanged by EA treatments. No difference in number of β 2-AR immunoreactive cells was found in PCO ova-
ries, while EA treatments in PCO rats significantly increase the amount of β 2-AR immunostained cells when compared to PCO 
group. Values are given as means ± SEMs. bp < 0.05 vs PCO group. Representative pictures of stained cells (some of them 
pointed by black arrows) are showed in Panels C- D. The β 2-AR was found expressed in degenerating corpora lutea (C) and 
follicles (D) in all of the experimental groups. Magnification C: ×400; D: ×200.
Control EA PCO PCO+EA
0
0.3
0.5
0.8
1.0
β
β
β
β
2
-
A
R
/
G
A
P
D
H
m
R
N
A
A
Control EA PCO PCO+EA
0
100
200
300
β
β
β
β
2
-
A
R
i
m
m
u
n
o
p
o
s
i
t
i
v
e
c
e
l
l
s
/
4
0
0
0
0
µ
µ
µ
µ
m
2
B
C D
a a
bReproductive Biology and Endocrinology 2005, 3:21 http://www.rbej.com/content/3/1/21
Page 10 of 13
(page number not for citation purposes)
Ovarian p75NTR mRNA and protein expression Figure 6
Ovarian p75NTR mRNA and protein expression. As shown in panel A, ovarian p75NTR mRNA was found unchanged in the 
PCO group compared to the control and EA group. Low-frequency EA treatments did not significantly affect ovarian 
p75NTRmRNA expression in the EA, PCO and PCO+EA groups. Values are given as means ± SEMs normalized to GAPDH. As 
shown in panel B, the number of ovarian p75NTR immunopositive cells was significantly decreased in the EA group when com-
pared to controls. The number of p75NTR-stained cells in the PCO group was significantly higher than in controls, while repeated 
EA treatments greatly decreased p75NTR protein immunoreactivity in the PCO+EA group. Values are given as means ± SEMs. ap 
< 0.05 vs control group. bp < 0.05 vs PCO group. Representative pictures of stained cells (pointed by black arrows) are 
showed in Panels C-D. The p75NTR was found expressed in the thecal layer of healthy follicles (C) and in the stromal region 
(D) in all of the experimental groups. Magnification C-D: ×200.
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frequency EA treatments, except for α 1b-AR. The EA treat-
ment also induced an increase of β 2 -AR protein in the EV-
injected rats.
It has been suggested that high sympathetic drive to the
ovary might be important in both EV-induced PCO in rats
and PCOS in humans [4,5,9,10,27]. Clinical studies show
that women with PCOS temporarily recover normal ovar-
ian function after bilateral wedge resection or ovarian
drilling, which partially denervates the ovary [28]. These
observations suggest that the ovarian nerves might be
involved in the successful outcome of bilateral wedge
resection and ovarian drilling. Current pharmacological
treatment using clomiphene citrate is the first-line treat-
ment for ovulation induction in women with PCOS [29].
This is effective, but side-effects such as super ovulation
are quite common [30]. There is a clear need to identify
new therapeutical approaches – including non-pharmaco-
logical strategies – to reduce or replace drug intervention.
That EA may reduce hyperactivity in the ovarian periph-
eral sympathetic nerve fibers is consistent with the theory
that EA could modulate sensory, motor, and autonomic
outflow at the segmental level [16]. It has also been
shown that EA activates higher control systems, resulting
in the release of a number of neuropeptides that are
important in the modulation of central and segmental
autonomic outflow and of the HPO axis [16,31]. We have
recently shown that repeated low-frequency EA induces
regular ovulations in more than one-third of women with
PCOS and normalizes endocrine and neuroendocrine
parameters without any negative side-effects [17]. The
effects of repeated low-frequency EA were then attributed
to an inhibition of hyperactivity in the sympathetic nerv-
ous system [16,32]. The present study further indicates
that EA is effective in preventing EV-induced dysregula-
tion of ovarian sympathetic markers.
Increased peripheral sympathetic outflow in rats with ster-
oid-induced PCO is evidenced by increased releases of
NE, higher concentrations of NE in the ovary, and a
reduced number of β 2-AR in the ovarian compartment
receiving catecholaminergic innervation [8,9]. The role of
β 2-AR in ovarian physiology and pathophysiology has
been related to the regulation of ovarian steroidogenesis
[8]. Transection of the superior ovarian nerve in steroid-
induced PCO reduces the steroid response, raises β 2-AR
expression to normal levels, and restores estrus cyclicity
and ovulation [8]. Thus the disturbances in steroid pro-
duction – at least in the present rat PCO model – might be
secondary to the elevated adrenergic control over ovarian
steroidogenesis mediated by β 2-AR. Interestingly,
repeated treatments of low-frequency EA induced an
increase of β 2-AR protein in EV-injected rats, and this is in
accordance with the hypothesis that EA down-regulates
the activity in the sympathetic nervous system. On the
other hand, the mRNA expression of β 2-AR was decreased
in the EA and in the PCO+EA group compared with the
control group. One plausible explanation for the discrep-
ancy between the mRNA and protein levels might be an
unbalanced turn over between β 2-AR mRNA and protein.
Thus the lower level of mRNA, compared to those of the
protein, could reflect its utilization for protein synthesis,
not balanced by an appropriate mRNA replacement. Such
a mechanism could also reflect different regulation levels
for our treatments, that could act on protein production
separately at both the gene transcription and protein syn-
thesis. Further studies are necessary to clarify this
mechanism(s).
The functional significance of the different α 1-ARs in the
ovary of PCO rats has not been clearly identified. The
function of these types of ARs has traditionally been char-
acterized in ovarian physiology as being primarily related
to the regulation of ovarian blood flow. Interestingly, α 1-
agonist stimulation has recently been shown to modulate
the progesterone release in cultured granulose cells by
potentiation of vasoactive intestinal peptide (VIP) and
Pituitary Adenylate Cyclase-Activating Polypeptide
(PACAP) [33]. In a recent study, for the first time to our
knowledge, we have shown that the expression of all α 1-
AR subtypes at both the mRNA and the protein level are
up-regulated at an early (30 day) and at a late (60 day)
stage after EV injection [14]. Thus it can be inferred that
α 1-ARs participate not only in the physiological regula-
tion of progesterone from the normal rat ovary [33], but
also most probably in the up-regulation of progesterone
release described in the EV-induced PCO ovary [8]. Fur-
thermore, the dysregulated α 1-ARs can be related to high
sympathetic activity in the ovaries of PCO rats [8]. Indeed,
we found that repeated treatments of low-frequency EA
prevents the dysregulation of α 1a-AR and α 1d-AR protein
in rats with steroid-induced PCO that evidence the effec-
tiveness of EA in reducing the sympathetic drive to the
ovary. The mRNA expression of α 1d-AR was normalized
by low-frequency EA, but not that of α 1a- and α 1b-AR.
Again, the discrepancy between the mRNA expression and
protein levels might be an unbalanced turn over between
α 1a- and α 1b-ARs mRNA and protein, thus the mRNA that
is engaged in the protein translation is not replaced com-
pletely, while this is not the case for α 1d-AR. These results
indicate that a mechanism linked to ovarian presence and
function of ARs could be active in this context.
The present results are in line with the results of a recent
study demonstrating that low-frequency EA increased
blood flow and decreased sympathetic activity in the
ovary [22,23]. These observations led to the hypothesis
that the effects of low-frequency EA on ovarian blood flow
were mediated by α 1-ARs [22], and this is in line withReproductive Biology and Endocrinology 2005, 3:21 http://www.rbej.com/content/3/1/21
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another recent study by Uchida et al. [12] which suggested
that the regulation of ovarian blood flow via sensory stim-
ulation is mediated by α 1-ARs evidenced by blocking α 1-
ARs.
In the present study, we also demonstrate that repeated
treatments of low-frequency EA maintains p75NTR mRNA
and protein amount at basal levels in PCO animals. This
agrees with results of our previous studies [18,20]. It is
known that p75NTR aids the development of specific pop-
ulations of sympathetic neurons [34], and that this recep-
tor is responsible for the responsiveness of adult
sympathetic neurons to target-derived NGF [35]. The evi-
dence that EV injection in adult rats increases the intrao-
varian synthesis of both NGF and p75NTR [10] suggests a
possible functional link between PCO and the NGF/NGF
receptor system. Interestingly, these changes were accom-
panied by selective activation of noradrenergic neurons
projecting to the ovary. The activation of the sympathetic
nervous system after EV injection has been evidenced by
enhanced TH activity in the ovaries of PCO rats [9] and by
increase of TH mRNA expression in the catecholaminergic
cells of the celiac ganglion selectively projecting to the
ovaries [10]. Furthermore, intraovarian blockade of NGF
and p75NTR  resulted in decreased p75NTR  synthesis by
ovarian theca cells and restored estrous cyclicity and ovu-
latory capacity in EV-injected rats [10]. Thus, one possible
mechanism underlying the effect of low-frequency EA on
sympathetic tone might be decreased p75NTR-mediated
sympathetic responsiveness to NGF action. That EA
counteracted the EV-induced increase in ovarian expres-
sion and amount of p75NTR supports this hypothesis.
Interestingly, CRF a principal neurohormone in the con-
trol of the hypothalamus-pituitary-adrenal (HPA) axis,
has been shown to be increased in both the median emi-
nence and in the ovary in rats with steroid-induced PCO
[19]. In the same study, repeated low-frequency EA
restored the increased CRF concentrations indicating that
peripheral CRF and the HPA axis plays a crucial role in the
regulation of ovarian function in steroid-induced PCO
[19]. These data, together with the present one, suggest
that EA could act as a modulator of the central control
over sympathetic output in rats with steroid-induced
PCO. Further studies are necessary to clarify this point.
In conclusion, the present study shows that EA prevented
most of the EV-induced changes in ovarian ARs. Further-
more, EA was able to counteract the EV-induced up regu-
lation of p75NTR, probably by normalizing the
sympathetic ovarian response to NGF action. Our data
indicate the effectiveness of EA in the regulation of ovar-
ian responsiveness to sympathetic inputs and depict a
possible complementary therapeutic approach to prevent-
ing and/or overcoming sympathetic-related anovulation
in women with PCOS.
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